Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 6/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909805 | 0.88 | ADORA1 (0.39) | ADORA1ADORA2AADORA2BBRAFPDE4A | |
| SCHEMBL4908408 | 0.81 | ALDH1A1 (0.42) | ADORA1ADORA2AADORA2B | |
| SCHEMBL4907550 | 0.78 | BRAF (0.42) | ADORA1ADORA2AADORA2BBRAFPDE4A | |
| SCHEMBL4909542 | 0.73 | CTSS (0.47) | ADORA1ADORA2AADORA2BBRAF | |
| SCHEMBL4900864 | 0.73 | MAPT (0.45) | ADORA1ADORA2APDE4BCYP1A2 | |
| SCHEMBL4908567 | 0.72 | ADORA2A (0.57) | ADORA1ADORA2AADORA2BBRAFPDE4A | |
| SCHEMBL4898242 | 0.71 | CTSL (0.50) | ADORA1ADORA2ABRAFPDE4APDE4B | |
| SCHEMBL4907704 | 0.70 | BRAF (0.69) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14281650 | 0.69 | BRAF (0.61) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4911723 | 0.69 | CTSK (0.37) | ADORA1ADORA2AADORA2BBRAFPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | ADORA1 529/4885ADORA2A 837/4885ADORA2B 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.